Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity

Bioconjugate Chemistry

Volumn 17, Issue 1, 2006, Pages 114-124

  Doronina, Svetlana O ^a   Mendelsohn, Brian A ^a   Bovee, Tim D ^a   Cerveny, Charles G ^a   Alley, Stephen C ^a   Meyer, Damon L ^a   Oflazoglu, Ezogelin ^a   Toki, Brian E ^a   Sanderson, Russell J ^a   Zabinski, Roger F ^a   Wahl, Alan F ^a   Senter, Peter D ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELLS; CONTROLLED DRUG DELIVERY; CYTOTOXICITY; MONOCLONAL ANTIBODIES; TARGETED DRUG DELIVERY; TUMORS;

ANTIBODY-DRUG CONJUGATES; ANTIMITOTIC AGENTS; CELL LINES; CYTOTOXIC ACTIVITIES; IN-VITRO; LINKER TECHNOLOGY; PHENYLALANINE RESIDUES; TUMOR MODELS; VITRO AND IN VIVO; VIVO ACTIVITY;

AMINO ACIDS;

ANTIMITOTIC AGENT; BEVACIZUMAB; CETUXIMAB; MONOCLONAL ANTIBODY; MONOMETHYLAURISTATIN F; RITUXIMAB; STATINE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE PERMEABILITY; CYTOTOXICITY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; HEMATOPOIETIC CELL; TARGET CELL; TECHNOLOGY; TUMOR MODEL; TUMOR XENOGRAFT;

EID: 31544441685     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc0502917     Document Type: Article

References (27)

1. Adams, G. P., and Weiner, L. M. (2005) Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147-57.
2. Baker, M. (2005) Upping the ante on antibodies. Nat. Biotechnol. 23, 1065-72.
3. Wu, A. M., and Senter, P. D. (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23, 1137-46.
4. Lambert, J. M. (2005) Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol. 5, 543-9.
5. Payne, G. (2003) Progress in immunoconjugate cancer therapeutics. Cancer Cell 3, 207-12.
6. Dubowchik, G. M., and Walker, M. A. (1999) Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol. Ther. 83, 67-123.
7. Smith, S. V. (2004) Technology evaluation: cantuzumab mertansine, ImmunoGen. Curr. Opin. Mol. Ther. 6, 666-74.
8. DiJoseph, J. F., Popplewell, A., Tickle, S., Ladyman, H., Lawson, A., Kunz, A., Khandke, K., Armellino, D. C., Boghaert, E. R., Hamann, P., Zinkewich-Peotti, K., Stephens, S., Weir, N., and Damle, N. K. (2005) Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol. Immunother. 54, 11-24.
9. Dubowchik, G. M., and Firestone, R. A. (1998) Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg. Med. Chem. Lett. 8, 3341-6.
10. Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., and Trail, P. A. (2002) Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjugate Chem. 13, 855-69.
11. Dubowchik, G. M., Mosure, K., Knipe, J. O., and Firestone, R. A. (1998) Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg. Med. Chem. Lett. 8, 3347-52.
12. Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., Francisco, J. A., Wahl, A. F., Meyer, D. L., and Senter, P. D. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21, 778-84.
13. Sanderson, R. J., Hering, M. A., James, S. F., Sun, M. M., Doronina, S. O., Siadak, A. W., Senter, P. D., and Wahl, A. F. (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res. 11, 843-52.
14. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., Meyer, D. L., and Francisco, J. A. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10, 7063-70.
15. Law, C. L., Cerveny, C. G., Gordon, K. A., Klussman, K., Mixan, B. J., Chace, D. F., Meyer, D. L., Doronina, S. O., Siegall, C. B., Francisco, J. A., Senter, P. D., and Wahl, A. F. (2004) Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin. Cancer Res. 10, 7842-51.
16. Wahl, A. F., Klussman, K., Thompson, J. D., Chen, J. H., Francisco, L. V., Risdon, G., Chace, D. F., Siegall, C. B., and Francisco, J. A. (2002) The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 62, 3736-42.
17. Trail, P. A., Willner, D., Lasch, S. J., Henderson, A. J., Hofstead, S., Casazza, A. M., Firestone, R. A., Hellstrom, I., and Hellstrom, K. E. (1993) Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261, 212-5.
18. Reeve, J. G., Rabbitts, P. H., and Twentyman, P. R. (1989) Amplification and expression of mdr1 gene in a multidrug resistant variant of small cell lung cancer cell line NCI-H69. Br. J. Cancer 60, 339-42.
19. Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., Law, C. L., Doronina, S. O., Siegall, C. B., Senter, P. D., and Wahl, A. F. (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102, 1458-65.
20. Sun, M. M., Beam, K. S., Cerveny, C. G., Hamblett, K. J., Blackmore, R. S., Torgov, M. Y., Handley, F. G., Ihle, N. C., Senter, P. D., and Alley, S. C. (2005) Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjugate Chem. 16, 1282-90.
21. Trail, P. A., Willner, D., Knipe, J., Henderson, A. J., Lasch, S. J., Zoeckler, M. E., TrailSmith, M. D., Doyle, T. W., King, H. D., Casazza, A. M., Braslawsky, G. R., Brown, J., Hofstead, S. J., Greenfield, R. S., Firestone, R. A., Mosure, K., Kadow, K. F., Yang, M. B., Hellstrom, K. E., and Hellstrom, I. (1997) Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates. Cancer Res. 57, 100-5.
22. Chari, R. V., Martell, B. A., Gross, J. L., Cook, S. B., Shah, S. A., Blattler, W. A., McKenzie, S. J., and Goldmacher, V. S. (1992) Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res. 52, 127-31.
23. Hamann, P. R., Hinman, L. M., Beyer, C. F., Greenberger, L. M., Lin, C., Lindh, D., Menendez, A. T., Wallace, R., Durr, F. E., and Upeslacis, J. (2005) An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. Bioconjugate Chem. 16, 346-53.
24. Hamann, P. R., Hinman, L. M., Beyer, C. F., Lindh, D., Upeslacis, J., Shochat, D., and Mountain, A. (2005) A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts. Bioconjugate Chem. 16, 354-60.
25. Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H. R., Upeslacis, J., Shochat, D., Mountain, A., Flowers, D. A., and Bernstein, I. (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chem. 13, 47-58.
26. Miller, M. L., Roller, E. E., Wu, X., Leece, B. A., Goldmacher, V. S., Chari, R. V., and Ojima, I. (2004) Synthesis of potent taxoids for tumor-specific delivery using monoclonal antibodies. Bioorg. Med. Chem. Lett. 14, 4079-82.
27. Ojima, I., Geng, X., Wu, X., Qu, C., Borella, C. P., Xie, H., Wilhelm, S. D., Leece, B. A., Bartle, L. M., Goldmacher, V. S., and Chari, R. V. (2002) Tumor-specific novel taxoid-monoclonal antibody conjugates. J. Med. Chem. 45, 5620-3.